Barinthus Biotherapeutics (BRNS) News Today $1.42 -0.07 (-4.39%) Closing price 08/1/2025 03:51 PM EasternExtended Trading$1.42 0.00 (0.00%) As of 08/1/2025 05:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock BRNS Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Barinthus Biotherapeutics plc American Depositary Shares (BRNS) Short ...July 18, 2025 | nasdaq.comBarinthus Biotherapeutics Stock (NASDAQ:BRNS) Insider TradesJuly 17, 2025 | benzinga.comBarinthus Biotherapeutics Stock (NASDAQ:BRNS), Short ... - BenzingaJuly 17, 2025 | benzinga.comBarinthus Biotherapeutics plc (BRNS) - Yahoo FinanceJuly 8, 2025 | finance.yahoo.comBRNS - Barinthus Biotherapeutics PLC ADR Key Metrics - MorningstarJuly 3, 2025 | morningstar.comMHere's Why We're Not Too Worried About Barinthus Biotherapeutics' (NASDAQ:BRNS) Cash Burn SituationApril 26, 2025 | finance.yahoo.comBarinthus Biotherapeutics price target lowered to $6 from $7.50 at Alliance Global PartnersMarch 26, 2025 | markets.businessinsider.comH.C. Wainwright Sticks to Its Buy Rating for Barinthus Biotherapeutics (BRNS)March 22, 2025 | markets.businessinsider.comWilliam Blair Remains a Buy on Barinthus Biotherapeutics (BRNS)March 21, 2025 | markets.businessinsider.comBarinthus Bio Reports Full Year 2024 Financial Results and Updates on Corporate DevelopmentsMarch 20, 2025 | globenewswire.comBarinthus price target lowered to $6 from $7.50 at Alliance Global PartnersFebruary 8, 2025 | markets.businessinsider.comBarinthus Biotherapeutics price target lowered to $3 from $5 at H.C. WainwrightJanuary 13, 2025 | markets.businessinsider.comBarinthus Biotherapeutics: Barinthus Bio Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial UpdateJanuary 10, 2025 | finanznachrichten.deBarinthus announces strategic focus in I&I, provides financial updateJanuary 10, 2025 | markets.businessinsider.comBarinthus Bio's UK COO, CFO To Leave, Plans To Cut 65% Headcount To Expand Cash RunwayJanuary 10, 2025 | markets.businessinsider.comBarinthus Bio Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial UpdateJanuary 10, 2025 | globenewswire.comBarinthus Biotherapeutics Appoints New Chief Scientific OfficerNovember 27, 2024 | markets.businessinsider.comBarinthus Bio Promotes SNAP-TI Co-inventor, Geoffrey Lynn, M.D., Ph.D. to Chief Scientific OfficerNovember 25, 2024 | globenewswire.comPromising Clinical Trials and Potential Functional Cure Drive Buy Rating for Barinthus BiotherapeuticsNovember 19, 2024 | markets.businessinsider.comPromising New Data from Hepatitis B Trial by Arbutus and BarinthusNovember 17, 2024 | msn.comArbutus and Barinthus announce new data from IM-PROVE II trialNovember 16, 2024 | markets.businessinsider.comBarinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb SeroconversionNovember 15, 2024 | globenewswire.comArbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis BNovember 15, 2024 | globenewswire.comBarinthus Biotherapeutics plc (NASDAQ:BRNS) Short Interest UpdateNovember 13, 2024 | marketbeat.comWilliam Blair Has Positive Estimate for BRNS FY2024 EarningsNovember 11, 2024 | marketbeat.comHC Wainwright Reaffirms "Buy" Rating for Barinthus Biotherapeutics (NASDAQ:BRNS)November 8, 2024 | marketbeat.comBarinthus Biotherapeutics (NASDAQ:BRNS) Posts Earnings Results, Beats Estimates By $0.23 EPSNovember 7, 2024 | marketbeat.comBarinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial ResultsNovember 6, 2024 | globenewswire.comBarinthus Bio Announces Late Breaking Presentation at AASLD 2024 – The Liver Meeting® and Attendance at November ConferencesOctober 31, 2024 | markets.businessinsider.comShort Interest in Barinthus Biotherapeutics plc (NASDAQ:BRNS) Drops By 13.0%October 29, 2024 | marketbeat.comBarinthus Bio gets Buy stock rating on trial progressOctober 4, 2024 | investing.comBarinthus Bio retains Buy rating from H.C. Wainwright with trial startSeptember 28, 2024 | uk.investing.comBarinthus Biotherapeutics: Barinthus Bio Initiates Phase 1 Clinical Trial of VTP-1000 for the Treatment of Celiac DiseaseSeptember 24, 2024 | finanznachrichten.deBarinthus Bio Initiates Phase 1 Clinical Trial of VTP-1000 for the Treatment of Celiac DiseaseSeptember 24, 2024 | finance.yahoo.comBarinthus Biotherapeutics plc (NASDAQ:BRNS) Sees Large Drop in Short InterestSeptember 14, 2024 | marketbeat.com1,513,644 Shares in Barinthus Biotherapeutics plc (NASDAQ:BRNS) Purchased by Alphabet Inc.September 3, 2024 | marketbeat.comBarinthus Biotherapeutics plc (NASDAQ:BRNS) Sees Large Decline in Short InterestAugust 29, 2024 | marketbeat.comResearch Analysts Offer Predictions for Barinthus Biotherapeutics plc's Q3 2024 Earnings (NASDAQ:BRNS)August 15, 2024 | marketbeat.comM&G Plc Invests $7.28 Million in Barinthus Biotherapeutics plc (NASDAQ:BRNS)August 13, 2024 | marketbeat.comBarinthus Biotherapeutics (NASDAQ:BRNS) Given New $9.50 Price Target at Alliance Global PartnersAugust 13, 2024 | marketbeat.comBarinthus Biotherapeutics (NASDAQ:BRNS) Releases Quarterly Earnings Results, Misses Expectations By $0.01 EPSAugust 11, 2024 | marketbeat.comBarinthus Bio Reports Second Quarter 2024 Update on Corporate Developments and Financial ResultsAugust 8, 2024 | stockhouse.comShort Interest in Barinthus Biotherapeutics plc (NASDAQ:BRNS) Increases By 223.9%July 25, 2024 | marketbeat.comHere's Why We're Watching Barinthus Biotherapeutics' (NASDAQ:BRNS) Cash Burn SituationJuly 24, 2024 | finance.yahoo.comBarinthus Biotherapeutics plc (NASDAQ:BRNS) Sees Significant Increase in Short InterestJune 30, 2024 | marketbeat.comBarinthus Biotherapeutics (NASDAQ:BRNS) Rating Reiterated by William BlairJune 13, 2024 | marketbeat.comBarinthus Biotherapeutics (NASDAQ:BRNS) Given New $3.00 Price Target at BarclaysJune 13, 2024 | marketbeat.comBarinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus InfectionsJune 12, 2024 | globenewswire.comBarinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis BJune 6, 2024 | globenewswire.comBarinthus Biotherapeutics plc (NASDAQ:BRNS) Short Interest Down 52.1% in MayMay 29, 2024 | marketbeat.com Get Barinthus Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BRNS and its competitors with MarketBeat's FREE daily newsletter. Email Address BRNS Media Mentions By Week BRNS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BRNS News Sentiment▼0.000.45▲Average Medical News Sentiment BRNS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BRNS Articles This Week▼00▲BRNS Articles Average Week Get Barinthus Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BRNS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies DRUG News Today TVRD News Today TRDA News Today ACIU News Today FENC News Today PRQR News Today TLSA News Today LRMR News Today DSGN News Today YMAB News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BRNS) was last updated on 8/3/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredEx-Hedge Fund Manager Uncovers $100 Trillion Land ShiftTrump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to u...Stansberry Research | SponsoredInvestigating the Most Controversial Stock on EarthTesla’s wild price swings may not be random after all. Hedge fund veteran Larry Benedict has uncovered a st...Brownstone Research | SponsoredThis New Rule Could Change EverythingA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredSell these "safe" blue chips immediatelyInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Barinthus Biotherapeutics PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Barinthus Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
